Your browser is no longer supported. Please, upgrade your browser.
Settings
APLT Applied Therapeutics, Inc. daily Stock Chart
APLT [NASD]
Applied Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.69 Insider Own23.70% Shs Outstand15.91M Perf Week4.19%
Market Cap158.15M Forward P/E- EPS next Y-2.60 Insider Trans- Shs Float10.84M Perf Month10.44%
Income- PEG- EPS next Q-0.49 Inst Own36.50% Short Float0.24% Perf Quarter0.00%
Sales- P/S- EPS this Y-285.80% Inst Trans115.71% Short Ratio1.23 Perf Half Y-
Book/sh2.87 P/B3.46 EPS next Y-7.90% ROA- Target Price24.33 Perf Year-
Cash/sh2.58 P/C3.85 EPS next 5Y- ROE- 52W Range7.95 - 11.20 Perf YTD5.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.23% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low25.03% ATR0.64
Employees9 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)60.48 Volatility6.53% 7.10%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close10.05
ShortableYes LT Debt/Eq0.00 EarningsSep 20 BMO Payout- Avg Volume20.80K Price9.94
Recom1.50 SMA208.12% SMA5010.95% SMA2007.87% Volume1,857 Change-1.09%
Jun-10-19Initiated Robert W. Baird Outperform $24
Jun-10-19Initiated Cowen Outperform
Jun-10-19Initiated Citigroup Buy $29
Aug-14-19 03:51PM  What Percentage Of Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Do Insiders Own? Simply Wall St. -5.66%
Aug-12-19 07:00AM  Applied Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire +5.94%
Aug-08-19 07:00AM  Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study GlobeNewswire -8.11%
Jun-24-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia GlobeNewswire
Jun-21-19 07:00AM  Applied Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire -6.59%
Jun-10-19 10:05AM  Applied Therapeutics Stock Jumps as Analysts Give It a Bullish Welcome Barrons.com +6.45%
Jun-07-19 07:30AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions GlobeNewswire
May-28-19 07:30AM  Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia GlobeNewswire
May-24-19 07:00AM  Applied Therapeutics to Present Data at ESC-HF Highlighting AT-001, a Novel, Potent and Selective Aldose Reductase Inhibitor for Treatment of Diabetic Cardiomyopathy GlobeNewswire
May-20-19 10:15PM  Applied Therapeutics Inc (APLT) President and CEO Shoshana Shendelman Bought $1.3 million of Shares GuruFocus.com
May-08-19 07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-07-19 10:46AM  The Applied Therapeutics IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.